Table 2.

Application and mechanism of ferroptosis inducers.

Ferroptosis inducers	Mechanisms	Phenotype	References
Erastin	Inhibit System xc−	ROS accumulation, lipid peroxidation, GSH depletion, SLC7A11 upregulation	[134]
Sulfasalazine	Inhibit System xc−	Lipid peroxidation, GSH depletion, SLC7A11 upregulation	[135, 136]
Sorafenib	Inhibit System xc−	Increased overall ROS level and mitochondrial ROS level, lipid peroxidation, GSH depletion	[137, 138]
RSL3	Inhibit GPX4	ROS accumulation, lipid peroxidation	[44]
Diallyl trisulfide	Inhibit GPX4	ROS accumulation, increase the labile iron pool	[149]
6-Gingerol	Inhibit GPX4	ROS accumulation, GSH depletion	[150]
Altretamine	Inhibit GPX4	Lipid peroxidation	[139, 144]
Dihydroartemisinin	Inhibit GPX4, elevate Fe2+ level	Increased overall ROS level and mitochondrial ROS level, lipid peroxidation, GSH depletion, decreased GPX4 and ATP level	[145]
FIN56	Degrade GPX4	Lipid peroxidation	[141]
DPI2	GSH depletion	Lipid peroxidation	[44]
Cisplatin	GSH depletion	ROS accumulation	[142]
Buthionine sulfoximine	GSH depletion	Lipid peroxidation, GSH depletion	[44]
Artesunate	Elevate Fe2+ level, GSH depletion	ROS accumulation, lipid peroxidation	[143, 148]
Flubendazole	Induce p53 express	ROS accumulation, decreased SLC7A11 and GPX4 level	[40]